Fighting Enteroviral Infections to Prevent Type 1 Diabetes

Enteroviruses (EVs), especially coxsackieviruses B (CVB), are believed to trigger or accelerate islet autoimmunity in genetically susceptible individuals that results in type 1 diabetes (T1D). Therefore, strategies are needed to fight against EV infections. There are no approved antiviral drugs curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nekoua, Magloire Pandoua, Mercier, Ambroise, Alhazmi, Abdulaziz, Sane, Famara, Alidjinou, Enagnon Kazali, Hober, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031364/
https://www.ncbi.nlm.nih.gov/pubmed/35456818
http://dx.doi.org/10.3390/microorganisms10040768
Descripción
Sumario:Enteroviruses (EVs), especially coxsackieviruses B (CVB), are believed to trigger or accelerate islet autoimmunity in genetically susceptible individuals that results in type 1 diabetes (T1D). Therefore, strategies are needed to fight against EV infections. There are no approved antiviral drugs currently available, but various antiviral drugs targeting viral or host cell proteins and vaccines have recently shown potential to combat CVB infections and may be used as new therapeutic strategies to prevent or reduce the risk of T1D and/or preserve β-cell function among patients with islet autoantibodies or T1D.

Ejemplares similares